Skip Navigation

Cardiovascular Research 2004 62(1):105-111; doi:10.1016/j.cardiores.2004.01.018
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kumagai, K.
Right arrow Articles by Saku, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumagai, K.
Right arrow Articles by Saku, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model

Koichiro Kumagai*, Hideko Nakashima and Keijiro Saku

School of Internal Medicine, Department of Cardiology, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan, Fukuoka 814-0180, Japan

* Corresponding author. Tel.: +81-92-801-1011x3366; fax: +81-92-865-2692. Email address: kxk{at}fukuoka-u.ac.jp

Objective: It has been recently reported that AF is associated with tissue inflammation. Statins reduce C-reactive protein (CRP) levels. However, the effect of statin on atrial fibrillation (AF) is unclear. The purpose of the present study was to evaluate the effect of statin on AF in a canine sterile pericarditis model. Methods: Sterile pericarditis was created in 20 dogs randomly assigned to two groups: a control group (10 dogs) and an atorvastatin treatment group (10 dogs). Atorvastatin was administered orally (2 mg/kg/day) beginning 1 week before the operation until the end of the study. Before and 2 days after the operation, CRP levels, the duration of induced AF, the atrial effective refractory period (AERP), and intra-atrial conduction time were determined. Results: Before the operation, there were no significant differences in any of the parameters between the two groups. On the second postoperative day, the atorvastatin group had a lower CRP level (7.6±0.5 versus 11.7±1.3 mg/dl, P<0.0001), a shorter AF duration (177±57 versus 534±189 s, P<0.0001), a longer AERP (138±6 versus 130±6 ms, P<0.01), and a shorter intra-atrial conduction time (46±3 versus 51±5 ms, P<0.01) than the control group. Conclusions: Atorvastatin can prevent maintenance of AF by inhibiting inflammation in the canine sterile pericarditis model. Atorvastatin may thus be a novel therapeutic agent for AF.

KEYWORDS Arrhythmias; Inflammation; Statins

{star} This study was supported in part by a grant from the Science Research Fund of Ministry of Education, Science and Culture, Japan.

Time for primary review 28 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
E. I. Rossman, K. Liu, G. A. Morgan, R. E. Swillo, J. A. Krueger, S. J. Gardell, J. Butera, M. Gruver, J. Kantrowitz, H. S. Feldman, et al.
The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model
J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1127 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
J. Sanchez-Quinones, F. Marin, V. Roldan, and G.Y.H. Lip
The impact of statin use on atrial fibrillation
QJM, November 1, 2008; 101(11): 845 - 861.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Circulation, September 16, 2008; 118(12): 1285 - 1293.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
C. W. Israel
Effect of statins in 'upstream therapy' of atrial fibrillation: better reliability with implantable cardiac monitors
Eur. Heart J., August 1, 2008; 29(15): 1798 - 1799.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Kourliouros, A. De Souza, N. Roberts, A. Marciniak, A. Tsiouris, O. Valencia, J. Camm, and M. Jahangiri
Dose-Related Effect of Statins on Atrial Fibrillation After Cardiac Surgery
Ann. Thorac. Surg., May 1, 2008; 85(5): 1515 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.